New Delhi, Sep 25
A new malaria monoclonal antibody is safe, well-tolerated, and can elicit protection in people with no prior exposure to the malaria-causing parasite, according to a study.
The phase 1 randomised controlled trial of the experimental monoclonal antibody MAM01, published in the journal The Lancet Infectious Diseases, showed that of the three malaria-naive adults given the highest study dose, none had parasites in their bloodstream up to 26 weeks later.
"Malaria-naive" refers to an individual who has never been exposed to the malaria parasite and therefore has no natural immunity to the disease.